Literature DB >> 34339032

PAX8, an Emerging Player in Ovarian Cancer.

Priyanka Gokulnath1, Amata Amy Soriano1, Tiziana de Cristofaro1, Tina Di Palma1, Mariastella Zannini2.   

Abstract

Ovarian Cancer is one of the most lethal and widespread gynecological malignancies. It is the seventh leading cause of all cancer deaths worldwide. High-Grade Serous Cancer (HGSC), the most commonly occurring subtype, alone contributes to 70% of all ovarian cancer deaths. This is mainly attributed to the complete lack of symptoms during the early stages of the disease and absence of an early diagnostic marker.PAX8 is emerging as an important histological marker for most of the epithelial ovarian cancers, as it is expressed in about 90% of malignant ovarian cancers, specifically in HGSC. PAX8 is a member of the Paired-Box gene family (PAX1-9) of transcription factors whose expression is tightly controlled temporally and spatially. The PAX genes are well known for their role in embryonic development and their expression continues to persist in some adult tissues. PAX8 is required for the normal development of Müllerian duct that includes Fallopian tube, uterus, cervix, and upper part of vagina. In adults, it is expressed in the Fallopian tube and uterine epithelium and not in the ovarian epithelium. Considering the recent studies that predict the events preceding the tumorigenesis of HGSC from the Fallopian tube, PAX8 appears to have an important role in the development of ovarian cancer.In this chapter, we review some of the published findings to highlight the significance of PAX8 as an important marker and an emerging player in the pathogenesis of ovarian cancer. We also discuss regarding the future perspectives of PAX8 wherein it could contribute to the betterment of ovarian cancer diagnosis and treatment.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Biomarkers; Cancer tissues; Metastasis; Ovarian cancers; PAX genes; Transcription factors

Mesh:

Substances:

Year:  2021        PMID: 34339032     DOI: 10.1007/978-3-030-73359-9_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  35 in total

1.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 2.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

3.  Are all pelvic (nonuterine) serous carcinomas of tubal origin?

Authors:  Christopher G Przybycin; Robert J Kurman; Brigitte M Ronnett; Ie-Ming Shih; Russell Vang
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

4.  TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.

Authors:  Elisabetta Kuhn; Robert J Kurman; Russell Vang; Ann Smith Sehdev; Guangming Han; Robert Soslow; Tian-Li Wang; Ie-Ming Shih
Journal:  J Pathol       Date:  2011-12-23       Impact factor: 7.996

Review 5.  Precursors and pathogenesis of ovarian carcinoma.

Authors:  D Lim; E Oliva
Journal:  Pathology       Date:  2013-04       Impact factor: 5.306

Review 6.  Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?

Authors:  Nelly Auersperg
Journal:  Gynecol Oncol       Date:  2013-04-02       Impact factor: 5.482

7.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Authors:  Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

Review 8.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors:  David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

Review 9.  The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin.

Authors:  Mirjana Kessler; Christina Fotopoulou; Thomas Meyer
Journal:  Int J Mol Sci       Date:  2013-03-25       Impact factor: 5.923

10.  Incessant ovulation and ovarian cancer - a hypothesis re-visited.

Authors:  M F Fathalla
Journal:  Facts Views Vis Obgyn       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.